Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.25259/NMJI_1190_2023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Sodium-glucose cotransporter 2 inhibitors in acute heart failure: the EMPULSE trial and literature review].
G Ital Cardiol (Rome)
December 2024
U.O.C. Cardiologia Clinica e Riabilitativa, Presidio Ospedaliero San Filippo Neri - ASL Roma 1, Roma.
In heart failure management, hospitalization is the main cause of medical costs and is associated with an increased risk of adverse events. This review reports evidence on hospitalization as the ideal setting for disease-modifying therapy implementation, with a particular focus on gliflozins in patients with stabilized acute heart failure. The authors analyze data from the EMPULSE trial, the largest clinical study that evaluated a gliflozin in acute heart failure in patients with both reduced and preserved systolic function.
View Article and Find Full Text PDF[Current Use of Sodium Glucose Co-transporter 2 Inhibitors in Heart Failure Therapy].
Turk Kardiyol Dern Ars
September 2024
Department of Cardiology, Dokuz Eylul University Faculty of Medicine, Izmir, Türkiye.
Article Synopsis
- Sodium-glucose cotransporter-2 inhibitors (SGLT2i) help lower blood glucose and sodium levels by promoting their excretion in urine, leading to benefits like reduced heart failure (HF) hospitalizations in patients with type 2 diabetes (T2DM) and cardiovascular (CV) risks.
- Clinical trials like DAPA-HF and EMPEROR-Reduced demonstrate that SGLT2i medications (dapagliflozin and empagliflozin) significantly reduce CV mortality and HF hospitalizations in heart failure patients, whether they have T2DM or not.
- Recent studies, including EMPEROR-Preserved and DELIVER, also support the effectiveness of SGLT2is in treating heart
EMPULSE trial: Time to use SGLT-2 inhibitors in acute heart failure?
Natl Med J India
September 2024
Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India.
Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post-hoc analysis from EMPULSE.
Eur J Heart Fail
September 2024
Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Aims: Patients hospitalized for acute heart failure (HF) could be enrolled in EMPULSE (NCT04157751) upon haemodynamic stabilization and between 24 h and 5 days after hospital admission. The timing of treatment initiation may influence the efficacy and safety of drugs such as empagliflozin. The aim of this study was to evaluate patient characteristics, clinical events, and treatment effects according to time from admission to randomization.
View Article and Find Full Text PDFTreatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trial.
Eur J Heart Fail
April 2024
University of Groningen Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
Aim: The EMPULSE (EMPagliflozin in patients hospitalised with acUte heart faiLure who have been StabilizEd) trial showed that, compared to placebo, the sodium-glucose cotransporter 2 inhibitor empagliflozin (10 mg/day) improved clinical outcomes of patients hospitalized for acute heart failure (HF). We investigated whether efficacy and safety of empagliflozin were consistent across the spectrum of left ventricular ejection fraction (LVEF).
Methods And Results: A total of 530 patients hospitalized for acute de novo or decompensated HF were included irrespective of LVEF.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!